Advances in genetics: widening our understanding of prostate cancer [PDF]
, 2016 Prostate cancer is a leading cause of cancer-related death in Western men. Our understanding of the genetic alterations associated with disease predisposition, development, progression, and therapy response is rapidly improving, at least in part, owing ...
A Heidenreich +85 more
core +3 more sources
Intratumoral steroidogenesis in castration-resistant prostate cancer: a target for therapy
Prostate International, 2014 Development of castration-resistant prostate cancer (CRPC) in a low androgen environment, arising from androgen deprivation therapy (ADT), is a major problem in patients with advanced prostate cancer (PCa).
Inna Armandari +3 more
doaj +1 more source
BMC Health Services Research, 2022 Background Using a standardized approach to describe the sources of uncertainty in cost-effectiveness analyses might bring added value to the local critical assessment procedure of reimbursement submissions in Hungary.
Gergő Merész +3 more
doaj +1 more source
The utility of PSMA and PSA immunohistochemistry in the cytologic diagnosis of metastatic prostate carcinoma [PDF]
, 2013 Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/107502/1/dc23075 ...
Bernacki, Kurt D. +2 more
core +1 more source
A narrative review of individualized treatments of genitourinary tumors: Is the future brighter with molecular evaluations? [PDF]
, 2021 Few molecular prognostic and predictive biomarkers have been identified so far in genitourinary tumors. We started from a literature search to explore the status of the art of molecular pathology tests as diagnostic, prognostic, predictive biomarkers in ...
Fiorentino M. +2 more
core +1 more source
Circulating Tumour DNA as a Biomarker Source in Metastatic Prostate Cancer
Société Internationale d’Urologie Journal, 2020 Tumour molecular features are increasingly linked to treatment response and patient prognosis in advanced prostate cancer. Plasma cell-free circulating tumour DNA (ctDNA) isolated from a minimally invasive blood draw offers a convenient source of tumour ...
Gillian Vandekerkhove, Alexander Wyatt
doaj +1 more source
Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program [PDF]
, 2014 [Abstract] BACKGROUND: Based on the TROPIC study results, cabazitaxel was approved for the management of metastatic castration-resistant prostate cancer (mCRPC) progressing on or after docetaxel.
Alfredo Sánchez-Hernández +10 more
core +2 more sources
Prostatic carcinomas with neuroendocrine differentiation diagnosed in needle biopsies, a morphologic study of 7 cases among 465 sequential biopsies in a tertiary cancer center [PDF]
, 2011 Purpose: Neuroendocrine carcinomas (NEC) of the prostate are rare, with only a few series hitherto reported. the objective of this study was to assess in a single institution the clinical and morphologic characteristics of neuroendocrine carcinomas ...
Franco, M. +5 more
core +2 more sources
First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings [PDF]
, 2020 Although both docetaxel and androgen-receptor-axis-targeted (ARAT) agents have yielded survival improvements in combination with androgen deprivation therapy (ADT) compared to ADT alone in metastatic castration-sensitive prostate cancer (mCSPC) patients,
Angelo Porreca +19 more
core +1 more source
Loss of the tumor suppressor, Tp53, enhances the androgen receptor-mediated oncogenic transformation and tumor development in the mouse prostate. [PDF]
, 2019 Recent genome analysis of human prostate cancers demonstrated that both AR gene amplification and TP53 mutation are among the most frequently observed alterations in advanced prostate cancer. However, the biological role of these dual genetic alterations
Aldahl, Joseph +14 more
core